Supplementary Materials

Supplementary Material for:

Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy

Marie-Claude Bourgeois-Daigneault,* Dominic Guy Roy, Amelia Sadie Aitken, Nader El Sayes, Nikolas Tim Martin, Oliver Varette, Theresa Falls, Lauren Elizabeth St-Germain, Adrian Pelin, Brian Dennis Lichty, David Francis Stojdl, Guy Ungerechts, Jean-Simon Diallo, John Cameron Bell*

*Corresponding author. Email: mbourgeois{at}ohri.ca (M.-C.B.-D.); jbell{at}ohri.ca (J.C.B.)

Published 3 January 2018, Sci. Transl. Med. 10, eaao1641 (2018)
DOI: 10.1126/scitranslmed.aao1641

This PDF file includes:

  • Fig. S1. Maraba efficiently infects and kills breast cancer PDXs and 4T1 tumors.
  • Fig. S2. Maraba treatment shows limited efficacy in murine TNBC models.
  • Fig. S3. Maraba treatment reduces lung metastases.
  • Fig. S4. The survival benefit conferred by Maraba in the tumor rechallenge model requires replicating virus and is tumor-specific.
  • Fig. S5. Local Maraba treatment provides systemic protection.
  • Fig. S6. Local Maraba treatment does not protect against lung metastasis in immunocompromised mice.
  • Fig. S7. Maraba infection induces the production of cytokines and chemokines.
  • Fig. S8. Maraba infection activates NFκB.
  • Fig. S9. Several chemokines are important for the chemoattractive activity of the Maraba-conditioned medium.
  • Fig. S10. Viable immune cells extracted from tumors were analyzed by flow cytometry.
  • Fig. S11. Maraba infection promotes T cell infiltration.
  • Fig. S12. The combination of Maraba and ICIs improves tumor control.

[Download PDF]